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Apoptotic dysregulation is a hallmark of mela­
noma pathogenesis and chemoresistance. Mu­
tations in TP53 occur infrequently in melanoma 
(Weiss et al., 1995; Zerp et al., 1999; Hocker 
and Tsao, 2007; Ji et al., 2012) and are not crit­
ical for tumor development (Stretch et al., 1991; 
Lassam et al., 1993; Kanoko et al., 1996; Zerp 
et al., 1999). Nevertheless, the TP53 apoptotic 
pathway is abrogated in melanoma; this may 
result from dysregulation of upstream (Matsuoka 
et al., 1998; Chehab et al., 2000; Hirao et al., 
2000; Shieh et al., 2000) or downstream TP53 
cell signaling (Bae et al., 1996; Satyamoorthy 
et al., 2000) or from alterations in other mem­
bers of the TP53 family (Tuve et al., 2006), in­
cluding the TP53 homologue TP63. To date, 
there is limited evidence to explain the mechanism 
or mechanisms of inactivation or attenuation 
of p53 tumor suppression in melanomagenesis. 
Whole genome array studies have demonstrated 
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The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly character-
ized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abro-
gated. This may result from alterations in TP53 family members, including the TP53 
homologue TP63. Here we demonstrate that TP63 has an antiapoptotic role in melanoma 
and is responsible for mediating chemoresistance. Although p63 was not expressed in 
primary melanocytes, up-regulation of p63 mRNA and protein was observed in melanoma 
cell lines and clinical samples, providing the first evidence of significant p63 expression  
in this lineage. Upon genotoxic stress, endogenous p63 isoforms were stabilized in both 
nuclear and mitochondrial subcellular compartments. Our data provide evidence of a  
physiological interaction between p63 with p53 whereby translocation of p63 to the 
mitochondria occurred through a codependent process with p53, whereas accumulation of 
p53 in the nucleus was prevented by p63. Using RNA interference technology, both iso-
forms of p63 (TA and Np63) were demonstrated to confer chemoresistance, revealing  
a novel oncogenic role for p63 in melanoma cells. Furthermore, expression of p63 in both 
primary and metastatic melanoma clinical samples significantly correlated with melanoma-
specific deaths in these patients. Ultimately, these observations provide a possible explana-
tion for abrogation of the p53-mediated apoptotic pathway in melanoma, implicating novel 
approaches aimed at sensitizing melanoma to therapeutic agents.
© 2013 Matin et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 
Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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1/20 (5%) desmoplastic melanomas (Kanner et al., 2010). 
Expression of TAp63 and Np63 in uveal melanoma was dem­
onstrated in 12/18 (66.7%) and 1/18 (5.6%) cell lines, respec­
tively (Kilic et al., 2008). Other studies have suggested a lack 
of p63 expression in melanoma in situ or invasive disease 
(Di Como et al., 2002; Dotto and Glusac, 2006; Bourne et al., 
2008; Morgan et al., 2008; Sakiz et al., 2009; Glusac, 2011).
The tissue­specific response of p63 to DNA damage is 
variable. The only study investigating p63 response in the me­
lanocyte lineage reported expression of two isoforms: TAp63 
and either TAp63 or Np63 (undetermined) in mouse me­
lanocytes with no endogenous up­regulation in mouse mela­
noma cells. In this mouse model, p63 isoforms were not 
induced upon DNA damage (Kulesz­Martin et al., 2005). In 
contrast, ectopically expressed TAp63 and  isoforms accu­
mulate in leukemic cells in response to UVB, UVC, doxoru­
bicin, and etoposide (Katoh et al., 2000; Okada et al., 2002). 
To support this, topoisomerase II inhibitors (doxorubicin and 
etoposide) but not UVB induced endogenous expression of 
TAp63 (and p53­target genes p21, 14-3-3-, GADD45, and 
PIG3) but not Np63 in mouse hepatocytes and human he­
patocellular carcinoma cells (Petitjean et al., 2005). A consis­
tent picture emerges whereby certain forms of DNA damage 
induce an apoptotic response mediated, at least in part, through 
degradation of antiapoptotic N isoforms (Liefer et al., 2000; 
Harmes et al., 2003) and stabilization of proapoptotic TA iso­
forms (Gressner et al., 2005).
There is intense debate as to whether, and how, p53 fam­
ily members interact with each other in apoptosis and tumor 
suppression (Benchimol, 2004). Induction of death by p53 re­
quires partnership of p63 and p73 in neurons and mouse em­
bryo fibroblasts (Flores et al., 2002). This effect may be tissue 
specific as p63 and p73 are not required for the induction of 
apoptosis in T cells (Senoo et al., 2004). In neuronal cells, al­
though p63 alone can promote neuronal apoptosis, it is also 
an obligate proapoptotic partner for p53 and essential for p53­
induced apoptotic cell death (Jacobs et al., 2005). In hepato­
cellular carcinoma, all three p53 family members were involved 
in the DNA damage response to genotoxic agents, revealing 
a central role for the p53/p63/p73 network in treatment re­
sponse and prognosis of this cancer (Gressner et al., 2005; 
Müller et al., 2006; Mundt et al., 2010; Schilling et al., 2010; 
Seitz et al., 2010).
p53 is best characterized as a nuclear transcription factor 
that transactivates various genes (Riley et al., 2008). It possesses 
biological activities that are cytosolic and transcription inde­
pendent. Data have demonstrated that p53 mutants lacking a 
transactivation domain can induce apoptosis (Kakudo et al., 
2005), and activation of p53 in the absence of a nucleus also 
triggers apoptosis (Chipuk et al., 2003), demonstrating that 
cytoplasmic p53 can induce apoptosis through a transactiva­
tion­independent mechanism. The transcription­independent 
p53­death pathway couples the nuclear and extranuclear ac­
tions of p53. In unstressed cells, cytosolic p53 is sequestered 
into an inactive complex by soluble cytosolic bcl­XL (B cell 
lymphoma–extra large). In response to stress, nuclear p53 
a failure of p53 to regulate target genes involved in cell cycle and 
apoptosis (Hoek et al., 2004; Prince et al., 2004; Karst et al., 2005; 
Vance et al., 2005; Avery­Kiejda et al., 2011), raising the possibil­
ity that aberrant functioning of the p53 pathway promotes mela­
noma progression (Avery­Kiejda et al., 2011).
High levels of p53 expression in melanoma cells and tissue 
samples have been reported in numerous studies (Bártek et al., 
1991; Stretch et al., 1991; Akslen and Mørkve, 1992; McGregor 
et al., 1993; Yamamoto et al., 1995; Hussein et al., 2003; Houben 
et al., 2011; Knopf et al., 2011). This is often in the absence of 
point mutations in the gene (McGregor et al., 1993; Albino 
et al., 1994; Sparrow et al., 1995) but is associated with tran­
scriptional inactivity (Houben et al., 2011). Moreover, corre­
lation of p53 immunoreactivity with advanced melanoma and 
unfavorable prognosis has been demonstrated (McGregor et al., 
1993; Yamamoto et al., 1995). Small molecular weight variants 
of p53 have also been demonstrated in melanoma and, in some 
instances, are expressed at higher levels than full­length WT­p53 
(Avery­Kiejda et al., 2008).
This study focuses on TP63, a gene which is tissue­ 
specifically transcribed into TA and N isoforms by two al­
ternative promoters (Osada et al., 1998; Yang et al., 1998). Both 
TA and N isoforms undergo three alternative splicing events 
at the C terminus, generating six different isoforms (Ikawa et al., 
1999; Yang and McKeon, 2000; Mills, 2006). More recently, 
two new C­terminal TP63 variants, named TP63  and , 
have also been identified, bringing the total number of TP63 
isoforms to 10 (Mangiulli et al., 2009). To date, the p63 pro­
teins display a diverse range of biological activities, impacting 
cells in an isoform­dependent but also cell type– and stimu­
lus­specific manner. p63 plays a complex role in tumorigene­
sis that is likely to be context specific (Flores et al., 2005; 
Keyes et al., 2005; Perez­Losada et al., 2005); p63 genomic 
locus amplification and/or overexpression of Np63 occurs 
in 80% of head and neck squamous cell carcinomas, support­
ing its role as an oncogene (Hibi et al., 2000; Yang and McKeon, 
2000; Choi et al., 2002; Hu et al., 2002; Massion et al., 2003; 
Mills, 2006).
The expression pattern of p63 isoforms has not been widely 
investigated in melanoma. Previous studies of p63 in melano­
cytes are conflicting; mouse melanocytes express two isoforms of 
p63, TAp63 and either TAp63 or Np63 (Kulesz­Martin 
et al., 2005), and cultured human eye melanocytes do not ex­
press TP63 (Kilic et al., 2008). Neither of these studies were 
adequate biological correlates for human cutaneous melano­
cytes: mouse melanocytes predominantly reside in the hair fol­
licle within the dermis, mice do not spontaneously develop 
melanoma (Bardeesy et al., 2000; Merlino and Noonan, 2003), 
and the molecular biology of ocular melanoma is distinct from 
cutaneous melanoma (Belmar­Lopez et al., 2008; Sato et al., 
2008; Shields et al., 2008). Studies using immunohistochemis­
try techniques to investigate expression of p63 protein in human 
melanoma have mostly used it as an example of negative re­
activity; in two tissue microarrays, Np63 was expressed in 
2/59 (3.4%) and 2/25 (8%) human melanomas (Reis­Filho 
et al., 2003a). A more recent study demonstrated expression in 
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isoforms were expressed in samples obtained from different 
body sites from a range of skin phototypes (Fig. 1 A). TAp63 
and Np63 were expressed in keratinocytes; the relative ex­
pression was in keeping with a previous study (Senoo et al., 
2007). TAp63 but not Np63 was also expressed in fibro­
blasts. RT­PCR analysis failed to detect expression of either 
isoform in primary melanocyte cultures, but both isoforms 
were expressed in a metastatic melanoma cell line (WM1158). 
Despite the apparent lack of TP63 expression in primary me­
lanocytes, quantitative PCR (Q­PCR) demonstrated signifi­
cant up­regulation of TP63 in 24/33 (73%) melanoma cell 
lines (Fig. 1 B). No correlation was observed between expres­
sion of either TAp63 and/or Np63 with BRAFV600E muta­
tion or NRAS mutation status (P > 0.05, Fisher’s exact test). 
In general, up­regulation of the two isoforms of TP63 was 
mutually exclusive with simultaneous up­regulation occurring 
infrequently (18%; n = 6). Western blotting data confirmed 
differential expression of p63 protein in melanoma cell lines 
compared with primary melanocyte cultures (Fig. 1 C).
Analysis of whole genome microarray data in melanoma 
tissue samples by Scatolini et al. (2010) revealed up­regulation 
of TP63 at all stages of melanoma progression but no signifi­
cant up­regulation of TP53 or TP73 (Fig. 1 D). Immuno­
histochemical expression of p63 was investigated in 40 primary 
melanoma tissue samples in a melanoma tissue microarray 
(mTMA; Biomax). Overall, 16/40 (40%) samples in the mTMA 
demonstrated strong labeling of p63 and costaining with HMB­
45 (human melanoma black­45), confirming expression of p63 
in melanoma cells; two examples are shown in Fig. 1 E. Statis­
tical analysis of clinical data available for the melanoma tissue 
array samples demonstrated no significant demographic differ­
ences between p63­positive and ­negative melanomas (Table S1).
p63 is responsive to DNA-damaging agents in melanoma 
and relocates to the mitochondrial compartment
Primary melanocyte cultures were treated with UVB radia­
tion and various chemotherapeutic agents (cisplatin, etoposide, 
and doxorubicin) from 6 to 48 h (Fig. 2 A and not depicted). 
No stabilization or reactivation of p63 was observed in me­
lanocyte cultures despite induction of DNA damage and 
induction of an apoptotic pathway. Upon DNA damage, up­
regulation of both nuclear and cytoplasmic p63 was observed 
in 8/9 (88%) established melanoma cell lines, with stabiliza­
tion occurring as early as 2 h and in some cell lines persisting 
for 48 h (not depicted). Stabilization of the p63 gene and 
protein was demonstrated in established melanoma cell lines 
treated with various DNA­damaging agents (Fig. 2, C and D). 
No induction of p63 was observed upon treatment with 
dacarbazine (not depicted). Treatment with novel BRAF 
inhibitors (PLX4032 and PLX4720) affected p63 expression 
in a cell line–specific manner with stabilization of p63 in some 
cases (Fig. 2, E and F).
Cytoplasmic stabilization of p63 in melanoma cell lines led 
to investigation of relocation of p63 to different subcellular 
compartments. MitoTracker Orange was used as a marker of 
mitochondria to investigate localization of extranuclear p63 
transactivates its target gene PUMA (p53 up-regulated modula-
tor of apoptosis), which liberates p53 to activate monomeric 
Bax (Bcl­associated X) in the cytosol (Chipuk et al., 2005).
Upon exposure to apoptotic stimuli, total cellular levels 
of p53 rapidly stabilize and a fraction accumulates at the 
mitochondria, where it controls a direct apoptotic program. 
Induced p53 rapidly translocates to the outer membrane of 
mitochondria, where it engages in inhibitory and activating 
complexes with the anti­ and proapoptotic members of the 
Bcl­2 family of mitochondrial permeability regulators (bcl­XL/
bcl­2 and BAK [BCL2­antagonist/killer], respectively). This 
translocation precedes changes of mitochondrial membrane 
potential, cytochrome c release, and caspase activation, which 
induces outer membrane permeabilization and the release of 
apoptotic activators (Sansome et al., 2001; Mihara and Moll, 
2003; Arima et al., 2005; Nemajerova et al., 2005; Moll et al., 
2006). Mitochondrial translocation of endogenous WT­p53 
occurs both in vitro and in vivo in response to various p53­
activating cellular stresses in different cell types (Sansome et al., 
2001; Mihara and Moll, 2003; Arima et al., 2005; Moll et al., 
2006). A recent study of melanocytes demonstrated translo­
cation of p53 to the mitochondria upon UVA irradiation but 
not UVB (Wäster and Ollinger, 2009).
The targeting of p53 to the mitochondria has received 
considerable interest. There is no reported mitochondrial trans­
location motif within the p53 polypeptide sequence, and 
N­ and C­terminal phosphorylation/acetylation modifica­
tions play no major role in mitochondrial targeting of p53 
(Nemajerova et al., 2005). Evidence suggests that monoubiqui­
tinylation of p53 provides a trafficking signal that redirects the 
cell from a fate of degradation and inactivation in unstressed 
cells to mitochondrial translocation and activation early during 
the stress response (Marchenko et al., 2007). Nuclear export 
of p53 is not necessary for mitochondrial translocation upon 
DNA damage, and instead distinct nuclear and cytoplasmic 
p53 pools become simultaneously and rapidly stabilized after 
genotoxic stress.
There is significant evidence to support a role for TP63 in 
carcinogenesis, and the tissue­specific expression of isoforms 
warrants exploration of this p53 family member in melanoma. 
To date, expression or function of TP63 in melanoma has not 
been systematically investigated. This study demonstrates a 
biological role for TP63 in melanoma through a dual mecha­
nism of negative regulation of apoptosis: through translocation 
of p63 to the mitochondria with consequent impact on ex­
pression of the BCl2 family proteins and through derepression 
of p53 in the nucleus. By identifying a functional interaction 
between TP63 and TP53, we provide a possible explanation 
for the notorious chemoresistance observed in melanoma.
RESULTS
p63 is expressed in melanoma cell lines  
and melanoma tissue samples
Primers designed to detect all splice variants of TAp63 (Koga 
et al., 2003) and Np63 (Yang et al., 1998) were used to de­
termine cellular expression in the skin. Both TA and N p63 
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Figure 1. p63 is expressed in melanoma cell lines and melanoma tissue samples. (A) TP63 expression in human normal skin cellular compo-
nents (RT-PCR). Controls included omission of cDNA. GAPDH was used as a loading control. (B) Q-PCR of TAp63 (39%, 13/33; top) and Np63 (51%, 
17/33; bottom) in panel of established primary melanoma and metastatic melanoma cell lines. The bars show the folds of p63 mean expression ± SD 
compared with mean expression of TP63/GUS in five primary melanocyte cultures (NHEM1, NHEM2, HEMa 3, HEMa V3, and HEMa V4). Measurements 
have been performed at least three times for each cell line at different passages. Dotted lines mark threefold increase in gene expression compared 
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that upon genotoxic stress, p63 translocates between the nu­
cleus, cytoplasm, and mitochondrial compartments to exert 
its function.
Fractionation using a novel flow cytometry technique  
can quantify relative p63 protein translocation  
to subcellular compartments
Subcellular fractionation enriches for p63 protein within each 
fraction but does not allow for assessment of changes in con­
centration of p63 in response to genotoxic stress. To quantify 
the relative concentration of p63 in different cellular com­
partments, a new method recently developed in our labora­
tory was used as an alternative to the fractionation technique 
(summarized in Materials and methods and Fig. 3 A; Leverrier 
et al., 2007).
A375M cells were treated with etoposide in a time­ 
dependent manner to establish the kinetic profile of p63 expres­
sion using flow cytometry (Fig. 3 A). To quantify the degree of 
p63 stabilization upon treatment, the percentage of positive 
events was combined with the relative fluorescent intensity 
of the Cy5 signal. Expression of p63 was determined by com­
paring the expression of p63 with the IgG mouse isotype con­
trol for each treatment. The relative concentration of p63 in 
treated A375M cells (considered total p63) and in fraction­
ated cells in the nuclei and mitochondria was calculated by 
comparing concentration of p63­Cy5 in each fraction for each 
treatment with the untreated sample (Fig. 3 A). Histograms 
demonstrate stabilization of total p63 to a maximum at 6 h 
with a reduction thereafter to 24 h (Fig. 3 A, i and ii). When 
cells were lysed and reanalyzed (Fig. 3 A, iii and iv), expres­
sion of nuclear p63 linearly increased to a maximum at 24 h, 
whereas the stabilization profile of mitochondrial p63 re­
flected that of total p63 (Fig. 3 A, iii and v).
Flow cytometry experiments confirmed stabilization of p63 
in both nuclear but to a greater extent in the mitochondri­
 al compartment in other fractionated melanoma cell lines, 
including WM1158 (metastatic melanoma) and SBCl2 (pri­
mary radial growth phase [RGP] melanoma) cells, upon treat­
ment with cisplatin, etoposide, and paclitaxel compared with 
untreated samples (Fig. 3, B and C; and not depicted). The 
purity of the subcellular fractions was confirmed using con­
focal microscopy (Fig. 3, D and E).
Posttranslational modifications, e.g., phosphorylation, of 
p63 are reported to significantly alter protein levels (Osada 
et al., 1998; MacPartlin et al., 2005; Westfall et al., 2005; Suh 
upon DNA damage. In untreated melanoma cells, localiza­
tion of p63 is largely confined to the nucleus (Fig. 2 E), but 
upon treatment with paclitaxel (as early as 3 h) stabilization of 
p63 was observed in the cytoplasm and, more specifically, in 
the mitochondria, as demonstrated by colocalization with 
MitoTracker Orange (Fig. 2 G). Similar effects were observed 
in melanoma cells treated with doxorubicin and etoposide 
(not depicted). Collectively, these data confirm that p63 is 
up­regulated in response to genotoxic stress and is localized 
to both nuclei and mitochondria.
Subcellular fractions of melanoma cell protein lysates were 
analyzed using Western blotting to enrich for proteins of 
interest within mitochondrial and nuclear fractions. Purity 
was confirmed by incubation with anti–Lamin A (nuclear), 
anti­mtHsp70 (mitochondrial heat shock protein 70; mito­
chondrial), and anti­GAPDH (cytosolic) antibodies. In un­
treated WM1158 cells, TAp63 was largely expressed in 
the nuclear fraction, whereas TAp63 was largely expressed 
in the mitochondrial compartment, with up­regulation of 
each isoform in their respective compartments in response 
to chemotherapeutic agents (Fig. 2 H). Results showed pre­
dominant p53 stabilization in the nucleus, with less pro­
nounced stabilization in mitochondria (Fig. 2 H). In support 
of this, immunofluorescence microscopy of the same cells 
confirmed nuclear stabilization upon DNA damage treat­
ment, suggesting that in melanoma cells, p53 also displays 
nuclear stabilization in response to genotoxic stress with 
possible translocation to the mitochondria (not depicted). 
In A375M cells, Np63 and Np63 were stabilized in 
nuclear and mitochondrial compartments upon treatment 
(not depicted).
Immunogold localization of protein using transmission 
electron microscopy was used to determine the exact loca­
tion of p63 within mitochondria. Treated A375M and 
WM1158 cells were pelleted, fixed, and processed for trans­
mission electron microscopy. Mitochondria were identi­
fied by their characteristic ultrastructure and confirmed by 
the presence of immunogold particles secondary to anti­
mtHsp70 antibody (Fig. 2, I and J). Upon treatment with 
paclitaxel, immunogold particles of p63 were demonstrated 
in the nucleus and the mitochondria of both cell lines using 
various anti­p63 antibodies (Fig. 2, I and J). No association 
of immunogold particles with other subcellular structures 
identified by their characteristic ultrastructure, e.g., the 
Golgi body, was observed (not depicted). These data suggest 
with mean expression in melanocyte cultures. GUS was used as an endogenous control. (C) 80 µg protein lysates from primary melanocyte cultures 
(NHEM and Hema) and melanoma cell lines probed for p63 (using anti-p63 antibody AB-4 which detects all isoforms of p63). GAPDH was used as 
loading control. (D) Analysis of mean expression ± SD of TP53 family genes in melanoma tissue samples using gene microarray (Agilent Technologies; 
Scatolini et al., 2010). VGP, vertical growth phase; Metastatic, melanoma metastases. (E) Immunofluorescence microscopy demonstrating expression 
of p63 in primary cutaneous melanomas (mTMA). (left) Primary melanoma from left arm (81-yr-old female). (right) Primary melanoma with heavy 
melanin deposition from right thumb (62-yr-old female). Panels described left to right, top to bottom: hematoxylin and eosin (H&E) labeling of mela-
noma, DAPI staining nuclei of melanoma cells, HMB-45 labeling melanoma cells, anti-p63 antibodies (H129/H137) labeling cells within tumor for p63, 
and merged image demonstrating coexpression of HMB-45 and p63 (yellow). Higher magnification confirms melanoma cells express p63 (yellow). 
Bars: (H&E thru Merge) 100 µm; (Merge, zoom) 50 µm.
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Figure 2. Upon genotoxic stress, p63 is stabilized in melanoma cells and partially relocates to the mitochondria. (A) Immunofluorescence mi-
croscopy of untreated melanocytes (Hema V3) and treatment with 50 mJ/cm2 UVB (for 24 h) or 10 µM cisplatin (for 24 h). Induction of DNA damage and 
apoptosis assessed using -H2AX and cleaved caspase, respectively. DAPI was used to stain nuclei. Images are representative of three independent experi-
ments. (B, top row) Untreated A375M cells contain low levels of endogenous p63 (detected by anti-p63 antibodies H129 and H137), which is largely nuclear. 
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observed with dacarbazine, even at increasing doses (Fig. 4, 
C and F; and not depicted). Treatment with novel BRAF inhibi­
tors (PLX4032 and PLX4720) significantly increased apoptosis 
of melanoma cells that were depleted of p63 (Fig. 4, I and J).
Upon treatment of WM1158 cells (sh­Ctrl) with etopo­
side or paclitaxel (16 h), induction of the mitochondrial apop­
totic pathway was demonstrated through cytosolic release of 
cytochrome c and up­regulation of Apaf­1 (apoptotic prote­
ase­activating factor 1; Fig. 4 D). Western blotting of WM1158 
cells treated with various chemotherapeutic agents demon­
strated significant stabilization of total and phosphorylated p53 
(ser­15), MDM2 (mouse double minute 2), and MDM4 in 
p63­depleted cells (Fig. 4 G). In addition, up­regulation of 
proapoptotic BCL2 proteins such as Bax, Bak, and Puma and 
down­regulation of antiapoptotic factors such as Bcl­xL, Mcl­1 
(myeloid cell leukemia 1), and Bcl­2 were detected in sh­p63 
cells exposed to cisplatin, etoposide, or paclitaxel (Fig. 4 G). 
Among the down­regulated antiapoptotic factors, Bcl­xL was 
consistently down­regulated by all the treatments in the ab­
sence of p63, whereas Mcl­1 expression was significantly de­
creased only by paclitaxel, which is reported to phosphorylate 
Bcl­2 (Yamamoto et al., 1999). A similar pattern of expression 
was also observed in A375M cells upon treatment with pacli­
taxel (Fig. 4 H), supporting a role for p53 and its downstream 
targets in the chemosensitivity conferred by depletion of p63. 
Treatment with BRAF inhibitors (PLX4032 and PLX4720) 
inhibited phosphorylation of BRAF downstream targets, e.g., 
phosphorylated ERK (extracellular signal­regulated kinase; 
P­ERK) and P­MEK (mitogen­activated protein/ERK), 
et al., 2006). Exposure to paclitaxel resulted in up­regulation 
of total phosphorylated p63 (ser 160/162), which constituted 
a small fraction of total p63 stabilized, as demonstrated using 
the flow cytometry fractionation method (Fig. 3 F). Stabiliza­
tion of phosphorylated p63 was maximal at 90 min and 3 h in 
the nuclear and mitochondrial fractions, respectively. These 
data show that in melanoma cells, upon DNA damage, p63 
could be phosphorylated in the nucleus before partially relo­
cating to the mitochondria.
Depletion of p63 sensitizes melanoma cells  
to a mitochondrial apoptotic pathway
Three oligonucleotide sequences were used to silence both 
TA and N p63 in melanoma cells (Fig. 4 A) to determine 
the effect on chemosensitivity. The morphology of A375M 
and WM1158 cells depleted of p63 using three different 
shRNA­p63 clones was not dissimilar to those stably express­
ing shRNA­scramble (not depicted). Significant depletion of 
p63 using all three shRNA­p63 clones (1, 2, and 3) was dem­
onstrated using Q­PCR and Western blotting in WM1158 
(Fig. 4 B) and A375M cells (Fig. 4 E). No difference in TAp63 
and Np63 mRNA expression was observed between non­
transfected melanoma cells and those stably expressing scram­
ble sequences, confirming the shRNA­scramble had no effect 
on p63 gene expression (Fig. 4, B and E). Depletion of p63 
using shRNA clones 1 and 2 in both WM1158 (Fig. 4 C) and 
A375M cells (Fig. 4 F) demonstrated significantly increased 
apoptosis upon treatment with etoposide, paclitaxel, and cis­
platin, as demonstrated by the Annexin V assay. No effect was 
Significant up-regulation of p63 (green) in both nuclear and cytoplasmic compartments of A375M cells was observed upon treatment with 20 µM etopo-
side (second row), 2 µM paclitaxel (third row), and 2 µM doxorubicin (bottom row) for 6 h. DAPI was used to stain nuclei (blue). Images are representative 
of three independent experiments. (C) RT-PCR demonstrating up-regulation of TA and/or N p63 expression in three melanoma cell lines, but not mela-
nocytes upon treatment with 10 µM cisplatin for 24 h. GUS was used as a loading control. (D) Western blot of A375M cells treated with cisplatin and UVB. 
The molecular masses of exogenously transfected p63 plasmids in HEK 293T cells were used to interpret specific p63 isoforms affected by the treat-
ment. Stabilization of both p63 isoforms and p53 demonstrates a dose-dependent effect. (E) RT-PCR of TAp63 in A375M and WM1158 cell lines treated 
with 3 µM PLX4032 for 24 h. GUS was used as housekeeping gene for mRNA standardization. (F) Q-PCR of Np63 expression in two BRAF mutated mela-
noma cell lines upon 24-h treatment with 3 µM PLX4032 or PLX4720. GUS was used as an endogenous control. Data show mean expression ± SD for at 
least three independent analyses performed in duplicates. (G) A375M cells labeled with MitoTracker Orange before treatment with 2 µM paclitaxel and 
immunofluorescence images shown at 6 and 9 h. DAPI was used to label nuclei. Images are representative of three independent experiments. (H) Western 
blot of WM1158 cells shows differential subcellular expression of p63 splice variants (TAp63 in the nuclear fraction and TAp63 in the mitochondrial 
fraction). This was confirmed by comparing molecular masses with exogenously transfected p63 plasmids in HEK 293T cells (far left six lanes). Treatment 
with various chemotherapeutic agents, M2/N2 cisplatin, M3/N3 doxorubicin, M4/N4 paclitaxel, M5/N5 etoposide, and M6/N6 UVB, corresponding to mito-
chondrial (M) and nuclear (N) fractions of the same cells. p53 expression was analyzed using anti-p53 antibody (DO-1), and mtHsp70 and Lamin-A were 
used as markers for mitochondrial and nuclear protein loading, respectively. Western blot data are representative of cellular fractionation experiments per-
formed in triplicate. (I) Transmission electron micrographs of immunogold labeling of p63 in mitochondria in A375M cells. Mitochondria are characterized 
by double membrane and cristae projections. (i) Negative control to confirm specificity comprises exclusion of primary antibody. (ii) Mitochondrion con-
firmed by electron-dense matrix surrounded by double membrane with cristae projections showing immunogold-labeled mtHsp70 localization within the 
mitochondrial matrix (black arrows). (iii–vi) Electron-dense mitochondria characterized by remarkably electron-dense mitochondrial matrix and cristae. 
Images demonstrate immunogold localization of p63 (using combination of anti-p63 antibodies H129 and H137) in cytosol, on mitochondrial mem-
branes, and within mitochondrial matrix (white arrows). (J) Transmission electron micrographs of immunogold labeling of p63 in mitochondria (WM1158 
cells). (i) Mitochondrion visualized by electron-dense matrix surrounded by double membrane with cristae projections showing immunogold-labeled 
mtHsp70 localization within the mitochondrial matrix (black arrows). (ii) Nuclear (labeled N) and extranuclear localization of p63. (iii) Electron-dense  
mitochondria characterized by electron-dense mitochondrial matrix and cristae. Image demonstrates immunogold localization of p63 (using combination 
of anti-p63 antibody H129) in transit to mitochondria and within mitochondrial matrix. (iv) Electron micrograph showing immunogold labeling of p63 
(using H137 anti-p63 antibody) within electron-dense mitochondrion matrix (arrow), and cristae are visible. Images are representative of three indepen-
dent experiments. Bars: (A, B, and G) 10 µm; (I [i–iii and v] and J [iii]) 100 nm; (I, iv and vi) 200 nm; (J, i, ii, and iv) 0.2 µm.
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Figure 3. Flow cytometry fractionation technique quantifies p63 translocation to subcellular compartments. (A) Kinetic profile of relative 
changes in p63 expression upon treatment with etoposide. (i) Scatter plot demonstrating intact A375M cells analyzed for p63-Cy5 expression in whole 
cells upon treatment with etoposide from 0 to 24 h. Antibody used in flow cytometry experiments detects all isoforms of p63. In A375M cells, the pre-
dominant isoform is Np63. (ii) Histogram demonstrates time course of up-regulation of total p63 in A375M cells. (iii) Scatter plot demonstrates analysis 
of lysed cells and gating of subcellular fractions (P1, whole cells; P2, nuclei; P3, mitochondria). (iv and v) Histograms demonstrating that up-regulation of 
p63-Cy5 in the nuclear fraction increases linearly after up to 24 h of treatment with etoposide (iv), whereas up-regulation of p63-Cy5 in the mitochondrial 
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the mitochondria (Fig. 5 D, right). These data suggest that 
translocation of p53 to the mitochondria may require p63, but 
more importantly, p63 physiologically prevents p53 nuclear 
stabilization in melanoma cells. Western blotting of nuclear 
extracts from A375M cells depleted of p63 after treatment 
with paclitaxel confirmed significant up­regulation of p53, 
particularly the phosphorylated forms at ser­15 and ser­46 
(the latter reported to link p53 with induction of apoptosis 
[Oda et al., 2000]), suggesting that up­regulation of p53 in the 
nucleus results in induction of the mitochondrial apoptotic 
pathway (Fig. 5 E). Moreover, immunoprecipitation with 
specific anti­p53 antibody in untreated A375M cells provides 
evidence of the endogenous interaction with p63 in mela­
noma cells (Fig. 5 F).
p63 reactivity in primary melanomas is a significant 
predictor of poorer outcomes
Immunohistochemistry of benign and malignant melanocytic 
lesions was undertaken to determine the effect of p63 reactiv­
ity on patient outcomes. Initially, paraffin­embedded samples 
of 31 benign intradermal nevi in 17 individuals (6 males and 
11 females) were analyzed for p63 expression (using H129 
anti­p63 antibody). Mean age at diagnosis was 50.1 yr (range 
33.9–70.2 yr). Positive internal control labeling of epidermal 
keratinocytes with p63 was used for specificity of staining. 
Overall, positive labeling of p63 in neval melanocytes was 
demonstrated with low frequency (3/31; 3.2%).
Overall, 81 paraffin­embedded primary cutaneous mela­
noma tissue samples from 80 individuals were analyzed for 
expression of p63. Mean age at diagnosis for primary melano­
mas was 58.4 yr (range 20.7–87.1 yr), male/female ratio was 
1:1.3, and median follow up was 4.0 yr (range 0.1–15.3 yr). 
The mean Breslow thickness was 3.1 mm (range 0.2–13.5 mm). 
Overall, 47/81 (58%) primary melanoma tissue samples dem­
onstrated positive labeling for p63 (Fig. 6 A). Statistical analy­
sis revealed no significant association between p63 expression 
whereas expression levels increased in those cells depleted of 
p63 (Fig. 4 K). Moreover, p53 was phosphorylated (at ser­15) 
in p63­depleted cells upon treatment with BRAF inhibitors, 
together with partial reduction in MDM2 expression and 
significant reduction in levels of MDM4.
Endogenous p63 prevents p53 nuclear stabilization  
and requires p53 to translocate into the mitochondria  
after DNA damage
Induction of p53 downstream targets and the mitochondrial 
apoptotic pathway raise the possibility that p63 may substi­
tute for or affect the apoptotic function of WT­p53 in mela­
noma. Flow cytometry fractionation experiments were used to 
delineate the relationship between p53 and p63, using mela­
noma cells depleted from p53 (si­p53 A375M cells). MDM2 
expression wasn’t affected in these cells although the expres­
sion of MDM4 significantly increased by depletion of p53 
(Fig. 5 A, top). When comparing these melanoma cells with 
the parental cell line expressing WT­p53 (A375M), upon treat­
ment with paclitaxel or etoposide, significantly greater total 
(Fig. 5 A), nuclear (Fig. 5 B), and mitochondrial p63 (Fig. 5 C) 
were observed in the WT­p53 melanoma cell line (A375M), 
suggesting that translocation of p63 to the mitochondria is 
dependent on the presence of p53. This was also further con­
firmed in p53­null melanoma cells (UISO­Mel­6) expressing 
mainly TAp63 isoform (Fig. 1 B). Upon treatment with pac­
litaxel, stabilization of TAp63 was predominantly observed in 
the nuclei (not depicted). Flow cytometry analysis demon­
strated up­regulation of total p63 protein levels upon treatment 
with limited stabilization in either nuclear or mitochondrial 
fractions (not depicted). Using the same flow cytometry quan­
tification method, significantly greater stabilization of total and 
nuclear p53 was observed in A375M sh­p63 cells compared 
with A375M sh­scramble cells upon treatment with etopo­
side or paclitaxel (Fig. 5 D, left and middle). In contrast, de­
pletion of p63 significantly decreased translocation of p53 to 
fraction occurs rapidly within 6 h (v). Data show mean expression of p63 ± SEM for three independent experiments performed in triplicate. (B) Histograms 
demonstrating effect of treatment with etoposide (6 h) in melanoma cell lines (A375M, WM1158, and SBCl2). Total p63 (top), nuclear stabilization (middle), 
and mitochondrial stabilization (bottom) of p63-Cy5 after treatment with etoposide using flow cytometry fractionation technique. (C) Histograms dem-
onstrating relative changes in p63 expression using flow cytometry fractionation technique after treatment with paclitaxel, cisplatin, and etoposide in 
WM1158 cells. Antibody used in flow cytometry experiments detects all isoforms of p63. In WM1158 cells, the predominant isoform is TAp63. Total p63 
levels stabilize in a time-dependent manner (top), nuclear stabilization of p63 is observed in WM1158 cells with all treatments (middle), and significantly 
greater mitochondrial p63 is stabilized in response to genotoxic stress (bottom). Data show mean protein expression ± SEM for at least three independent 
experiments performed in duplicate. (D) Validation of flow cytometry fractionation technique. A375M cells were labeled as outlined and homogenized 
before analysis using the FACSAria cell sorter. Gated fractions include whole cells, nuclei, and mitochondria that were subjected to FACS and then reana-
lyzed demonstrating purity of nuclear, mitochondrial, and whole cell fractions. Background noise signal derived from buffers (PBS and Hepes) was ex-
cluded. Nuclear and mitochondrial cell fractions were then visualized using confocal microscopy, confirming once again purity of the sorted fraction. 
Image examples provided are from one of five independent experiments performed. (E) p63-Cy5 expression in cellular fractions obtained from FACS of 
labeled A375M cells. Cells were labeled with fluorescence markers for nuclei (Hoechst) and MitoTracker Orange (mitochondria) and p63-Cy5 to label p63 
in A375M cells. Confocal microscopy analysis demonstrates p63-Cy5 expression in pure nuclear (i) and mitochondrial (ii) fractions of A375M cells. (iii) Giant 
mitochondria show colocalization (yellow) of p63-Cy5 and MitoTracker Orange, confirming validity of the flow cytometry method of quantification of p63 
translocation to the mitochondria. Images are representative of five independent experiments. (F) Comparison of total p63-Cy5 and phosphorylated p63 
assessed in intact cells upon treatment with 2 µM paclitaxel. Kinetic analysis of subcellular lysates for phosphorylated p63 after homogenization in 
nuclei (middle) and mitochondria (right) demonstrate nuclear stabilization of phosphorylated p63 in response to paclitaxel as early as 1.5 h. Data show 
mean protein expression ± SEM for at least three independent experiments performed in duplicate.
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Figure 4. Depletion of p63 by shRNA-p63 clones increases chemosensitivity. (A) Pictorial representation of TAp63 (top) and Np63 (bottom) 
genes demonstrating targeted sequences used by various RNAi oligonucleotides (1, 2, and 3) designed to target regions in both TA and N isoforms of 
p63. (B) Q-PCR (left) and Western blot (right) demonstrating knockdown of TAp63 gene and protein achieved in three shRNA-p63 clones. GUS was used 
as endogenous comparator for Q-PCR and GAPDH for Western blot. Data show mean ± SD of three independent experiments. (C) Percentage of apoptotic 
cells (Annexin V positive) displayed as mean ± SEM for three independent experiments performed in duplicate. Apoptosis in WM1158 shRNA-p63 cells 
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analysis using Cox regression analysis for metastatic tumors 
demonstrated that p63 status was a significant predictor of death 
from melanoma (multivariate analysis HR 3.86 [1.31–11.39]; 
P = 0.01; Table 2 and Fig. 6 E).
DISCUSSION
TP63, the master initiator of epithelium stratification, is often 
dysregulated in cancer progression (Koster et al., 2006; Mills, 
2006; Marchini et al., 2008). To date, the expression pattern 
of p63 isoforms has not been robustly investigated in the me­
lanocyte lineage. Q­PCR analysis, which displays increased 
sensitivity for detecting low expression levels of isoforms, dem­
onstrated infrequent expression of TP63 isoforms in primary 
human melanocyte cultures but significantly elevated expres­
sion in >70% of established melanoma cell lines. In contrast 
with previous immunohistochemistry studies, which showed 
little or no expression of p63 protein (Brinck et al., 2002; 
Di Como et al., 2002; Reis­Filho et al., 2003b; Dotto and 
Glusac, 2006; Bourne et al., 2008; Morgan et al., 2008; Sakiz 
et al., 2009; Kanner et al., 2010), our data provide the first evi­
dence of marked up­regulation of both p63 mRNA and pro­
tein in melanoma cell lines.
In an attempt to characterize the functional role of p63 in 
melanoma, we demonstrate stabilization of endogenous TA 
and N p63 isoforms in both nuclear and mitochondrial com­
partments of melanoma cells in response to genotoxic stress. 
Depletion of p63 by RNA interference (RNAi) revealed that 
the expression of TA and/or N p63 isoforms confers resis­
tance to chemotherapy in melanoma cell lines and provides 
evidence for an oncogenic role of p63 in this tumor. We have 
demonstrated through immunoprecipitation experiments that 
p53 and p63 can interact and have shown that stabilization of 
both p63 and p53 occurs in the nucleus and both are able to 
translocate to the mitochondria upon genotoxic stress. The 
mechanism for the latter process appears to be one of codepen­
dence, whereby depletion of one protein limits translocation 
of the other. We propose a mechanism that supports an inter­
action between p63 and p53 in melanoma cells, whereby de­
pleting p63 results in activation of the p53 mitochondrial 
apoptotic pathway, rendering melanoma sensitive to both stan­
dard chemotherapies and novel BRAF inhibitors. Our data 
suggest a putative antiapoptotic role for p63 by repression of 
of primary tumor with age at diagnosis, gender, or site of mela­
noma (Table S2). Analyses of histopathological prognostic fac­
tors demonstrated significant correlation with Breslow thickness 
(P = 0.03) but no other features (e.g., histological classifica­
tion, growth phase, ulceration status, regression, and mitotic 
rate; Table S2).
For these primary tumors, the mean time to recurrence 
(n = 7) was 1.60 yr (range 0.04–6.02 yr). Univariate and mul­
tivariate analysis demonstrated a trend toward increased re­
currence rates in p63­positive tumors but a nonsignificant 
association (P = 0.197, Wald test; not depicted). Mean time to 
first metastasis in this cohort (n = 30) was 1.44 yr (range 0.1–
4.69 yr). Univariate and multivariate analysis demonstrated 
an upward trend toward increased metastatic rates in the p63­
positive cohort but failed to reach significance (P = 0.105, 
Wald test; not depicted).
Overall mortality rate for the primary melanoma cohort 
was 33% (n = 26), and melanoma­specific mortality was 21% 
(n = 17). Median time to death was 2.6 yr (range 0.5–6.2 yr). 
Univariate and multivariate analysis using Cox regression analy­
sis for primary tumors demonstrated p63 status to be a sig­
nificant predictor of worse melanoma­specific outcomes in 
the univariate analysis (hazard ratio [HR] 3.10; P = 0.04, 
Cox proportional HR; Table 1 and Fig. 6 B).
p63 reactivity in metastatic melanomas  
is a significant predictor of poor outcomes
Overall, 19 recurrent melanoma samples and 56 metastatic 
melanoma tumor samples from 49 individuals (22 males and 
27 females) were analyzed. The median age at diagnosis was 
60.6 yr (range 30.6–107.6 yr). The median follow up for this 
cohort was 1.52 yr (range 0.04–8.07 yr). The proportion of 
p63­positive tumors comprised 10/19 (53%) of recurrent tu­
mors (Fig. 6 C) and 37/56 (66%) of metastatic tumors (Fig. 6 D). 
Statistical analysis revealed no significant association between 
p63 expression of metastatic tumor with age at diagnosis, gen­
der, or site of metastasis (Table S3).
Overall mortality for recurrent and metastatic tumors was 
45% (n = 22), and melanoma­specific mortality was 37% 
(n = 18). Median age of death was 62.4 yr (range 30.7–86.7 yr), 
with median time to death from first recurrence/metastases be­
ing 1.25 yr (range 0.08–6.43 yr). Univariate and multivariate 
compared with shRNA-scramble cells upon treatment with 10 µM cisplatin, 2 µM paclitaxel or 10 µM etoposide, and 200 µM dacarbazine. (D) Western 
blot of cytosolic fractions of WM1158 upon treatment with paclitaxel or etoposide (16 h) in cells with scramble-shRNA and those depleted of p63 using 
sh-RNA. (E, left) Q-PCR of cells transfected with three different shRNA-p63 sequences demonstrates significant reduction of Np63 in A375M cells for 
all three when compared with shRNA-scramble–transfected cells. Data show mean expression ± SD for at least three independent analyses performed in 
duplicates. (right) Western blot of A375M cells demonstrates significant silencing of Np63 protein levels (the predominantly expressed isoform) by 
shRNA p63 clones 1 and 2. (F) Percentage of apoptotic cells (Annexin V positive) displayed as mean ± SEM for three independent experiments performed 
in duplicate. Apoptosis in A375M shRNA-p63 cells compared with shRNA-scramble cells upon treatment with 10 µM cisplatin, 2 µM paclitaxel or 10 µM 
etoposide, and 200 µM dacarbazine. (G) Protein expression of p53 and selected downstream targets in cells depleted of p63 exposed to cisplatin, etopo-
side, or paclitaxel treatment. (H) Protein expression of p53 and selected downstream targets in A375M cells depleted of p63 upon treatment with pacli-
taxel. (I and J) Apoptosis in WM1158 shRNA-p63 (I) and A375M shRNA-p63 (J) cells compared with shRNA-scramble cells upon 24-h treatment with  
two BRAF inhibitors (3 µM PLX4032 or PLX4720). Percentage of apoptotic cells (Annexin V positive) is displayed as mean ± SEM for three independent 
experiments performed in duplicate. (K) Protein expression of selected BRAF downstream targets and p53 regulators in A375M cells depleted of p63 upon 
treatment with 3 µM PLX4032 or PLX4720 for 24 h.
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using a variety of methods and demonstrated a physiological 
role for this gene in melanoma. Although physical localization 
of p63 to the mitochondria has not been previously reported, 
here we have shown using a range of methods (immuno­
fluorescence, electron microscopy, Western blot of subcel­
lular fractionation, and FACS quantification analysis) that 
translocation of both TA and N p63 to the mitochondria 
occurs relatively rapidly compared with a more gradual 
stabilization of the protein in the nucleus, suggesting in­
volvement of p63 in the mitochondrial apoptotic pathway, 
while still retaining nuclear transcriptional activity. This is 
the first study to demonstrate p63 relocation to the mito­
chondria but also to quantify the stabilization in various 
subcellular compartments using a novel flow cytometry 
fractionation technique.
nuclear p53, which may be one explanation for the failure of 
p53 apoptotic function in melanoma.
To support these findings, we have provided the first evi­
dence that a significant proportion of cutaneous melanoma 
tumors express p63 protein. These data demonstrate nuclear 
and cytoplasmic expression of p63 in 40–63% of melanoma 
tissue samples, depending on stage of disease progression. 
Analysis of the p63­positive population demonstrated a sig­
nificant association with Breslow thickness of primary mela­
noma and a positive trend toward shorter time to recurrence 
and to metastases. Moreover, individuals with p63­postive 
primary and metastatic tumors had significantly worse disease­
specific outcomes.
This study has demonstrated the endogenous expression 
of p63 in melanoma cell lines and melanoma tissue samples 
Figure 5. Endogenous p63 prevents p53 nuclear stabilization and requires p53 to translocate into the mitochondria after DNA damage. 
(A, left) Protein expression of p53, MDM2, and MDM4 in A375M cells depleted of p53 (transient transfection 48 h). GAPDH was used as a loading 
marker. (right) Profile of relative changes in total p63 expression using flow cytometry fractionation technique in a p53-null melanoma cell line 
(A375M si-p53) compared with the parental control cell line (A375M si-Ctrl) upon treatment with paclitaxel and etoposide (6 h). (B and C) Compari-
son of nuclear (B) and mitochondrial (C) p63 protein stabilization in A375M si-p53 versus the parental cell line expressing WT-p53 (A375M si-Ctrl). 
Data show mean protein expression ± SEM for at least three independent experiments performed in duplicate. (D) Histograms showing relative 
changes in p53 expression in A375M scramble cells and A375M sh-p63 cells upon treatment with paclitaxel or etoposide (6 h); total (left), nuclear 
(middle), and mitochondrial (right) p53 in p63-depleted cells compared with scramble-control. (A and D) Data show mean protein expression ± SEM 
for at least three independent experiments performed in duplicate. (E) Western blot of total and phosphorylated p53, MDM2, and MDM4 derived from 
nuclear extracts of scramble-A375M cells and sh-p63 cells after treatment with paclitaxel (6 h). PCNA nuclear marker was used as a loading marker. 
(F) Immunoprecipitation (IP) of endogenous p53 in untreated A375M cells reveals physiological interaction with Np63. Input: A375M total lysates. 
HEK293 cells were transfected with Np63  as a loading marker control. WB, Western blot.
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Figure 6. p63 is a novel prognostic indicator in primary and metastatic melanoma. (A) Example of immunohistochemistry of primary mela-
noma: 36-yr-old male, nonulcerated, superficial spreading melanoma from trunk, Breslow thickness 3.5 mm. (i) Hematoxylin and eosin stain. (ii) Anti-
p63 antibody demonstrating strong nuclear labeling of epidermal keratinocytes confirming positive internal control. (iii) Higher magnification of 
melanoma cells showing nuclear and cytoplasmic p63 reactivity. (B) Kaplan-Meier survival estimates (melanoma specific) in the primary melanoma 
cohort (n = 81) demonstrate p63 reactivity to be a significant predictor of poorer outcomes (univariate analysis HR 3.10; P = 0.04, Cox proportional 
HR). (C) Example of recurrent melanoma (72-yr-old male) on arm. (i) Hematoxylin and eosin stain. (ii) Anti-p63 antibody demonstrating strong nuclear 
labeling of epidermal keratinocytes confirming positive internal control. (iii) Higher magnification confirming both nuclear and cytoplasmic p63 reactiv-
ity. (D) p63 reactivity demonstrated in three different lymph nodes completely replaced with metastatic melanoma in an 81-yr-old male. Low (i) and 
high (ii) magnifications of same node are shown, as well as two other lymph nodes (iii and iv); all three nodes demonstrate nuclear and cytoplasmic 
labeling of melanoma infiltration. Bars: (A and C [i and ii] and D [i]) 100 µm; (A and C, iii) 30 µm; (D, ii–iv) 50 µm. (E) Kaplan-Meier survival estimates 
(melanoma specific) in the metastatic melanoma cohort (n = 56) demonstrate p63 reactivity to be a significant predictor of poorer outcomes (multi-
variate analysis HR 3.86; P = 0.01, Cox proportional HR).
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Table 1. Cox regression analysis of melanoma-specific mortality for primary melanoma archival tissue samples
Clinicopathological factors Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis (yr) 1.04 (1.01–1.07) 0.014
Gender
Female 1
Male 1.36 (0.53–3.47) 0.517
Site of melanoma
Head/neck 1
Extremities 0.47 (0.10–2.10) 0.32
Acral 0.80 (0.13–4.79) 0.806
Trunk 1.14 (0.31–4.24) 0.847
Breslow thickness
T1 1
T2 - -
T3 - -
T4 17.30 (2.25–133.27) 0.006
Clark level
II 1
III 3.53 (0.39–31.66) 0.259
IV 5.04 (0.64–39.88) 0.125
V 14.29 (1.59–128.58) 0.018
Histological classification
ALM 1
NMM 3.13 (0.41–23.87) 0.27
SSM 0.44 (0.05–4.25) 0.477
Growth phase
RGP 1
VGP 6.85 (0.91–51.63) 0.062
Ulceration status
No 1 1 0.00
Yes 7.25 (2.38–22.12) 0.001 7.04 (2.30–21.50)
Mitotic rate (number/mm2)
Stage 1 1
Stage 2 1.09 (0.18–6.57) 0.922
Stage 3 4.63 (1.21–17.69) 0.025
Stage 4 4.77 (0.79–28.90) 0.089
Regression
No 1
Yes 0.25 (0.03–1.87) 0.176
Microsatellites
No 1
Yes 4.63 (1.73–12.39) 0.002
Recurrence
No 1
Yes 1.50 (0.34–6.57) 0.588
Metastases
Nil 1
Lymph - -
Multiple - -
p63 status
Negative 1 1 0.074
Positive 3.10 (1.02–9.48) 0.047 2.77 (0.91–8.51)
ALM, acral lentiginous melanoma; NMM, nodular melanoma; SSM, superficial spreading melanoma; VGP, vertical growth phase. P-values are from Cox proportional HR. For Breslow 
thickness categories, T1, 0–1 mm; T2, 1–2 mm; T3, 2–4 mm; and T4, >4 mm. Clark level defines depth related to skin structures: level I, melanomas confined to the outermost layer of the 
skin, the epidermis; level II, penetration by melanomas into the second layer of the skin, the dermis; level III, melanomas invade deeper through the dermis but are still contained 
completely within the skin; and level IV, penetration of melanoma into the fat of the skin beneath the dermis, penetration into the third layer of the skin, the subcutis. Mitotic rate 
categories were chosen based on significant survival differences demonstrated between these groupings (Azzola et al., 2003). “-” indicates that there were not enough values in each 
subcategory to undertake an analysis.
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Our data propose a physiological interaction between p53 
and p63, providing an explanation for the failure of p53­ 
mediated apoptosis in melanoma, in particular in response to 
chemotherapeutic agents. Although both TA and Np63 iso­
forms can act as transcription factors when homodimerized, 
the N isoforms can heterooligomerize with the TAp63 iso­
forms (as well as with other p53 family members) and modify 
their activity in vitro (Hibi et al., 2000; Choi et al., 2002; Serber 
et al., 2002; Chan et al., 2004). This could be a result of hetero­
oligomer formation or co­translocation by molecular chaperones 
recognized to transport p53, e.g., hsp90 or hsp70 (Walerych et al., 
2004, 2009; Whitesell and Lindquist, 2005).
Endogenous p63 prevents nuclear p53 stabilization after a 
stress response. This effect could be caused by either inhibi­
tion of p53 entry into the nucleus or, more likely, an inhibi­
tory effect on stability of p53 through induction of ubiquitin 
ligases, e.g., MDM2, which is often overexpressed in mela­
noma and recognized as one of the main causes of p53 inac­
tivity in melanoma cells (Polsky et al., 2002; Muthusamy et al., 
2006; Ji et al., 2012). Reactivating p53 to restore its tumor­
suppressive capacity has received great attention, with emphasis 
on reduction of mdm2 to achieve this (Smalley et al., 2007; 
Gomez­Monterrey et al., 2010; Michaelis et al., 2011; Verhaegen 
et al., 2012). Recently, elevated expression of MDM4 was 
demonstrated to be a key determinant of impaired p53 func­
tion in melanoma (Gembarska et al., 2012). Although previous 
in vitro data indicate that both MDM2 and MDM4 could not 
repress transactivation of p63 isoforms (Little and Jochemsen, 
2001), our results suggest otherwise in melanoma. Our data 
propose a role for p63 in modulating expression of p53, MDM2, 
and MDM4 through depletion of MDM2 (possibly through 
degradation) and MDM4, thus increasing p53­mediated che­
mosensitivity in melanoma. We have demonstrated that de­
pletion of p63 significantly increases nuclear expression of 
p53 and mdm2 in conjunction with total MDM4 protein lev­
els. Although we cannot definitively confirm whether p63 
directly represses MDM2 and MDM4 in addition to p53, or 
whether this is an indirect effect caused by their feedback 
Posttranslational modification analysis of p63 revealed that 
phosphorylation occurs within 3 h of exposure to genotoxic 
agents, predominantly in the nucleus but also in the mitochon­
dria. This may affect stability of the protein and/or its transac­
tivation abilities. Phosphorylation of p63 in keratinocytes has 
no effect on subcellular localization (Westfall et al., 2005), 
whereas it has been shown recently that phosphorylation of 
p53 may have a role in targeting the protein to the mitochon­
dria (Nemajerova et al., 2005; Mancini et al., 2009). Based on 
these data, we speculate that, analogous to p53, phosphoryla­
tion of p63 may contribute to the stability of the protein in 
the nucleus and may also assist in targeting the protein to the 
mitochondria. Further work is required to characterize tar­
geting of p63 to the mitochondria.
p63 has been linked to chemosensitivity in several tumors: 
in head and neck squamous cell carcinoma, Np63 was a key 
determinant of therapeutic response (Rocco et al., 2006), and 
expression correlated with clinical response to cisplatin (Zangen 
et al., 2005); in breast cancer, p63 expression positively corre­
lated with chemosensitivity to cisplatin (Rocca et al., 2008); and 
in hepatoma cells, transfection of TAp63 sensitized cell lines 
to chemotherapy and transient depletion led to chemoresistance 
(Gressner et al., 2005). Studies have reported p63 to be a bio­
marker for poor prognosis and cancer progression in breast can­
cer and follicular cell lymphoma, respectively (Ribeiro­Silva 
et al., 2003; Fukushima et al., 2006). Although p63 has been 
reported to primarily be a nuclear protein (el­Deiry et al., 1995; 
Dellavalle et al., 2001; Di Como et al., 2002), aberrant cyto­
plasmic expression is reported in lung and prostate cancers 
(Narahashi et al., 2006; Dhillon et al., 2009) and was associated 
with increased prostate cancer–specific mortality, reduced apop­
tosis, and higher proliferative activity, suggesting an oncogenic 
role in prostate cancer progression and survival (Dhillon et al., 
2009). Our data support these findings in melanoma. The het­
erogeneity of this cancer raises the possibility that such a finding 
could provide a novel therapeutic approach aimed at counter­
acting p63 expression in melanoma cells and consequently sen­
sitizing melanoma to standard chemotherapeutic agents.
Table 2. Cox regression analysis of melanoma specific mortality for metastatic melanoma archival tissue samples
Clinicopathological factors Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis (yr) 1.03 (1.00–1.07) 0.053 1.03 (1.01–1.06) 0.01
Gender
Female 1
Male 1.27 (0.55–2.94) 0.579
Site of metastatic melanoma
Lymph node 1 1
Other sitesa 1.95 (0.86–4.41) 0.108 2.29 (1.10–4.75) 0.026
p63 status
Negative 1 1 0.014
Positive 3.27 (1.08–9.87) 0.035 3.86 (1.31–11.39)
P-values are from Cox proportional HR.
aSkin, lung, parotid, and brain.
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and 1× EDTA­free Complete Protease Inhibitor tablet [Roche]) for 15 min 
on ice. Extracts were separated on SDS 10 or 12% polyacrylamide gels and 
transferred to a nitrocellulose transfer membrane (Whatman). The blots were 
incubated with the specific antibodies and developed according to the man­
ufacturer’s instructions (ECL plus; GE Healthcare).
Mitochondrial extracts. This was adapted from published methods (Mihara 
and Moll, 2003; Arnoult, 2008). Three 10­cm dishes of cells at a confluency 
of 70–80% were required to obtain sufficient levels of mitochondrial protein. 
All steps were performed on ice or at 4°C. Each plate was washed once with 
1 ml ice­cold PBS/1 mM EDTA before scraping the cells into a 15­ml falcon 
tube. Cells were pelleted at 750 g for 5 min and then washed in 3 ml ice­cold 
PBS. The cells were pelleted again for 5 min at 750 g. The pellet was then re­
suspended in 400 µl of cold mitochondrial isolation buffer (MIB) with pro­
tease inhibitor cocktail (PIC; 1:20). Cells were transferred to an ice­cold 
Dounce homogenizer (Wheaton) and homogenized with a minimum of 150 
strokes, while monitoring under the microscope. Trypan blue staining was 
used to confirm cell membrane disruption. The solution was transferred to an 
Eppendorf and centrifuged for 5 min at 800 g to isolate the nuclear fraction. 
The pellet was used for nuclear isolation. The supernatant was centrifuged for 
30 min at 10,000 g where the resulting pellet contained the mitochondrial 
fraction. The supernatant containing cytoplasmic proteins was added to the 
Eppendorf containing the nuclear fraction that was to be used in the nuclear 
isolation protocol. The mitochondrial pellet was washed in 500 µl of 1× MS 
buffer (+PIC) and centrifuged again at 10,000 g for 15 min. The mitochon­
drial fraction was resuspended in 50 µl MIB with 1% Triton­X 100. Protein 
concentration was determined and assayed using SDS­PAGE.
Nuclear and cytoplasmic extracts. The nuclear pellet and cytoplasmic 
supernatant from the mitochondrial extract method were resuspended and 
centrifuged at 900 g for 5 min at 4°C. The supernatant was discarded. The 
pellet was resuspended in 300 µl nuclear isolation (NI) lysis buffer supple­
mented with PIC and incubated on ice for 15 min. This was centrifuged 
at 3,500 rpm for 10 min at 4°C. The supernatant was transferred to a new 
Eppendorf­labeled cytoplasmic fraction. The pellet was resuspended again in 
300 µl ice­cold NI lysis buffer (+PIC) and centrifuged at 3,500 rpm for 10 min 
at 4°C, and supernatant was transferred to the cytoplasmic fraction Eppen­
dorf. The nuclear pellet was washed in 1 ml ice­cold Tris­EDTA twice and 
centrifuged at 3,500 rpm for 10 min at 4°C between each wash. The super­
natant was discarded each time. The pellet was resuspended in 300 µl ice­
cold TGN lysis buffer (+PIC) and incubated on ice for a total of 30 min, 
vortexing every 10 min. The sample was centrifuged again at 15,000 rpm for 
30 min at 4°C. The protein concentration of the supernatant containing 
nuclear proteins was determined and assayed using SDS­PAGE.
Immunoprecipitation
Cells were lysed in NP­40 lysis buffer and precleared with protein G beads 
for 1 h at 4°C. The protein concentration was determined, and then 1 mg of 
the extract was incubated either with p53 or control IgG antibody prebound 
to protein G beads for 4 h or overnight at 4°C. The beads were washed 
twice in NP­40 lysis buffer and twice in 100 mM NaCl, 1 mM EDTA, and 
10 mM Tris, pH 8. The immunoprecipitation beads were mixed with 5× 
Laemmli buffer and loaded onto an SDS–polyacrylamide gel. The gels were 
transferred (wet) to nitrocellulose membranes, and the resulting blots were 
incubated with specific antibodies and developed according to the manufac­
turer’s instructions (ECL plus).
RNA isolation, RT, and Q-PCR analysis
RNA was extracted from keratinocytes, fibroblasts, melanocytes, and melanoma 
cells by using the RNeasy kit (QIAGEN). A total of 500 ng RNA was 
used for using the SuperScript III RT kit (Invitrogen).The primers 
used for the PCR were as follows: Np63 forward, 5­GGAAAACA­
ATGCCCAGACTC­3; and reverse 5­GAAGGACACGTCGAAAC­
TGTG­3; TAp63 forward, 5­GGTGCGACAAACAAGATTGAG­3; 
and reverse, 5­GAAGGACACGTCGAAACTGTG­3; TP53 forward, 
loop with p53 (Li et al., 2010), these data support a role for 
p63 to disrupt the p53–MDM2 and p53–MDM4 axis in mel­
anoma with consequent reactivation of chemosensitivity. We 
propose that expression of p63 in melanoma might be con­
sidered when designing novel targets aimed at disrupting the 
p53–MDM2 and/or p53–MDM4 interactions.
In summary, we have demonstrated the first evidence of 
a biological role for p63 in melanoma cells supporting prefer­
ential up­regulation of TP63 over p53 mutations, whereby p63 
acts to negatively regulate p53 function. In response to DNA 
damage, p63 is stabilized in the nuclei and translocates to the 
mitochondria where it acts to repress apoptosis through di­
rect and indirect inhibitory function on proapoptotic effec­
tors in the p53 apoptotic pathway. These data unexpectedly 
implicate both TA and N p63 isoforms in mediating che­
moresistance in melanoma and impact novel therapeutic 
strategies used to treat melanoma.
MATERIALS AND METHODS
Cell lines
33 established melanoma cell lines and 8 human primary melanocytes cul­
tures were profiled (Tables S4 and S5). Human melanoma cell lines WM35, 
WM1575, WM1552C, WM793, WM115, WM278, WM1158, WM9, 
WM852, WM983B, and WM239A were donated by M. Herlyn (Wistar In­
stitute, Philadelphia, PA). SBCl2 RGP­like cells were a gift of B.C. Giovanella 
(Stehlin Foundation for Cancer Research, St. Joseph Hospital, Houston, TX). 
LM3, LM4, LM5, LM32, LM34, and LM37 were provided by M. Rodolfo 
(Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy). VMM39, Mel 
224, Mel 505, Mel 501, SK­MEL 5, and SK­MEL 24 were provided by 
T. Crook (University of Dundee, Dundee, Scotland, UK). DX3, DX3LT5.1, 
and A375M were donated by J.F. Marshall (Queen Mary University of London 
[QMUL], London, England, UK). C8161 cells were a gift from M.J.C. Hendrix 
(Children’s Memorial Research Center, Chicago, IL). SK­MEL 31, HBL, and 
MALME­3M were provided by J. Vachtenheim (University Hospital Prague, 
Prague, Czech Republic) and by G.E. Ghanem (University of Brussels, Brussels, 
Belgium). p53­null MM­AN cells were a gift from B.A. Gilchrest (Boston 
University School of Medicine, Boston, MA), whereas UISO­mel­6 were 
provided by T.K. Das Gupta (University of Illinois at Chicago, Chicago, IL). 
Detailed methods for cell culture and conditioned media are provided in 
Table S5. HEK293 cells were cultured in DMEM supplemented with 10% 
fetal bovine serum and 1% penicillin–streptomycin.
Antibodies
The antibodies used were GAPDH and APAF1 from Abcam; anti­p63 4A4 
from Neomarkers (for Western blot) and H­129/H137 from Santa Cruz 
Biotechnology, Inc. (for immunofluorescence); anti­BAK from EMD Milli­
pore; anti–cytochrome c from BD; anti–Bcl­XL (H­62), anti–MDM­2 (C­18/
N­20), anti­Bcl2 (C­8), and anti­p53 (DO­1) from Santa Cruz Biotechnology, 
Inc.; anti–phospho­p53 (ser15), anti–phospho­p53 (ser46), anti–Mcl­1, and 
anti­Puma from Cell Signaling Technology; and anti­Hdmx/MDM4 from 
Bethyl Laboratories, Inc.
Transfection and DNA-damaging treatments
p63 plasmids were donated by G. Melino (University of Leicester, Leicester, 
England, UK). HEK293 cells were transfected with Lipofectamine 2000 
reagent (Invitrogen) at a 1:2 ml/mg ratio with DNA using 5 mg plasmid 
DNA. Cells were treated with UV­B as indicated in the figure legends. 
Cisplatin, etoposide, doxorubicin, dacarbazine, and paclitaxel were used as 
indicated in the figure legends.
Western blot analysis
Cells were washed in PBS and then lysed using lysis buffer (1 M Tris, 2.5 M 
NaCl, 10% glycerol, 0.5 M glycerophosphate, 1% Tween 20, 0.5% NP­40, 
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intensities were then processed and combined with the Resolver SE System 
(Rosetta Biosoftware). Mean expression intensities and SEs for the TP63, 
TP53, and TP73 genes in the three sample classes were retrieved, as shown 
in Fig. 1 D.
Fluorescent immunocytochemistry
Cultured cells. Cultured cells were plated onto glass coverslips (confluency 
of 150,000 cells/cm2) in 12­well culture plates and allowed to attach over­
night at 37°C. Media was discarded and replaced with media containing 
MitoTracker Orange (dilution 1:10,000). Cells were incubated with Mito­
Tracker Orange for 30–40 min before washing twice in PBS followed by 
treatment with either UVB or pharmacological drug. Cells were washed in 
PBS for 5 min at 5–24 h after treatment, fixed in 1 ml of 4% formaldehyde/
PBS for 10 min at room temperature, washed twice in fresh PBS for 5 min, 
and stored at 4°C in PBS. PBS was removed from the cells, and 1 ml of 0.1% 
Triton X­100 in PBS was added for 3 min at room temperature to allow 
permeabilization of the cell membranes. Cells were washed twice with PBS 
for 10 min to remove residual detergent. To avoid nonspecific reaction with 
the secondary antibody, cells were incubated with 500 µl of 5% goat serum/
PBS for 30 min. After removal of the serum, cells were incubated with pri­
mary antibody diluted in 5% goat serum/PBS overnight at 4°C. Cells were 
washed three times for 10 min in PBS and incubated with secondary anti­
body for 1 h at room temperature in the dark. Cells were washed again three 
times for 10 min in PBS and incubated with 500 µg/ml DAPI (Invitrogen) 
for 10 min, followed by two further washes in PBS for 10 min at room tem­
perature. Coverslips were mounted onto a glass slide using Vectashield mount­
ing medium (Vector Laboratories) to prevent photobleaching over time. 
Mounted slides were sealed with clear colorless nail varnish and stored at 4°C 
protected from light.
mTMA. Immunohistochemical expression of p63 was investigated in an 
mTMA (Biomax US ME481) comprising a panel of 8 normal skin cores and 
40 melanoma cores, each of 1.5­mm diameter and 5 µM. The slide was ini­
tially baked at 60°C for 2 h. Tissue sections were subjected to deparaffiniza­
tion and rehydration using a xylene and ethanol (EtOH) series: (a) xylene: 
×2 at 5 min each, (b) 100% EtOH: twice at 5 min each, (c) 90% EtOH: once 
at 3 min, (d) 70% EtOH: once at 3 min, (e) 50% EtOH: once at 3 min, (f) 
distilled water: once at 5 min, and (g) PBS: once at 5 min. The slide was in­
cubated in citrate buffer, pH 6, placed in a microwave at 300 W for 5 min 
for three cycles, and subsequently cooled for 15 min. It was returned to the 
microwave for 5 min at 300 W, cooled to room temperature, and incubated 
in 5% goat serum/PBS for 2 h at room temperature. The slide was placed in 
a humid chamber and incubated with the primary antibody (1:50 dilution of 
H137 and H129 anti­p63 antibodies) overnight at 4°C. It was washed in 
PBS buffer (three times for 10 min) and incubated with the secondary anti­
bodies at room temperature in 5% goat serum/PBS for 1 h. It was washed in 
PBS (two times for 10 min) followed by 10 min in DAPI in 500 µg/ml PBS 
and washed (two times for 10 min) in PBS to remove excess DAPI. The slide 
was mounted using Vectashield to prevent bleaching of fluorophores. HMB­
45 was used and is a highly specific marker routinely used in the diagnosis of 
primary and metastatic melanoma cells to confirm melanoma cells (Colombari 
et al., 1988; Baisden et al., 2000; Yaziji and Gown, 2003).
RNAi
For p63 knockdown, A375M and WM1158 cell lines were transfected with 
a SMARTpool of three siRNAs targeting TP63 (ID 217143, ID 4893, and 
ID 217144; Applied Biosystems). Transfection was performed according to 
the manufacturer’s protocol and optimized for a 6­well plate. Cells were 
plated at 50% confluency subjected to transfection the following day using 
HiPerFect (QIAGEN) transfection reagent and 60 nM final concentration 
of each siRNA. Transfection media was replaced with complete RPMI­
1640 media after 24 h. p63 protein expression was analyzed by Western blot 
at 48 h after transfection. Cells incubated with the transfection reagent only 
(control) as well as cells transfected with a pool of nontargeting siRNAs 
(siCONTROL nontargeting siRNA pool) were used as negative controls. 
5­GTCACTGCCATGGAGGAGCCGCA­3; and reverse, 5­GACG­
CACACCTATTGCAAGCAAGGGTTC­3; GAPDH forward, 5­CTCC­
TCCACCTTTGACGCTG­3; and reverse, 5­CCACCCTGTTGCTG­
TAGCCA­3; and GUS forward, 5­AAACGATTGCAGGGTTTCAC­3; 
and reverse, 5­CTCTCGTCGGTGACTGTTCA­3.
Q­PCR reactions were set up in 96­well plates using Brilliant II SYBR 
Green QPCR Master Mix (Agilent Technologies). This Master Mix includes 
a SureStart Taq DNA polymerase with hot start capability and contains 
MgCl2 at a concentration of 2.5 mM in the 1× solution. A passive reference 
dye (ROX) was added to the mix to compensate for non­PCR–related vari­
ations in fluorescence. 25­µl reactions were set up. Experimental reactions 
were performed in triplicate, and duplicate no­template controls were also 
run. Once sample cDNA was added, the 96­well plate was briefly centri­
fuged to remove bubbles and ensure mixing. Data were collected by running 
a three­step cycling protocol using the AB7500 Fast Real­time PCR System 
(Applied Biosystems). The temperature cycler was set to detect and report 
fluorescence during the annealing and extension step of each cycle. Forma­
tion of nonspecific products was checked using gel analysis. TP63 gene ex­
pression levels in samples were standardized to the housekeeping gene, 
­glucuronidase (GUS). GUS was chosen because of its stable expression in 
melanoma cell lines and because it was a medium­expressed gene that was 
appropriate because of the medium­low expression levels detected for Np63 
in RT­PCR experiments. TP63/GUS expression levels in samples were 
compared with the mean of gene expression levels in the five primary mela­
nocyte cultures to determine the extent of up­regulation of p63 in melanoma 
cell lines considering a threefold increase in gene expression as a stringent 
cut­off for significant up­regulation.
Sequencing
RNA was extracted from melanoma cells by using the RNeasy kit, and cDNA 
was obtained by RT using the SuperScript III RT kit (Invitrogen) according 
to the manufacturer’s instructions. B­RAF (exon 15 for mutations at codon 
600) and N­RAS (exons 1–2 for mutations at codons 12, 13, and 61) genes 
were amplified by PCR with BIOTAQ DNA Polymerase (Bioline) and 
sequenced with different primers pairs: B­RAF forward, 5­GCACAGGGC­
ATGGATTACTT­3; and reverse, 5­ATTAATCTCTTCATGGCTTT­3; 
and N­RAS forward, 5­CGCCGACTGATTACGTAGC­3; and reverse, 
5­TCGCCTGTCCTCATGTATTG­3.
PCR products were sequenced using the BigDye Terminator version 
3.1 Cycle Sequencing kit (Applied Biosystems). 0.3 µl PCR product was 
added to a reaction containing 1 µl BigDye terminator mix (version 3.1; Ap­
plied Biosystems), 1 µl of 10 µM primer, and 3 µl Better Buffer (Microzone) 
made up to 11.5 µl with dH2O. The following PCR cycle for Sanger se­
quencing was performed: 95°C for 10 s (25 cycles), followed by 58°C for 15 s 
(25 cycles) and 60°C for 4 min (25 cycles). Sequencing reactions were trans­
ferred to plates and precipitated with 2.5 µl of 125 mM EDTA and 30 µl 
ice­cold 100% ethanol, left on ice for 10 min, and centrifuged at 4,400 g for 
20 min. Plates were inverted and centrifuged at 135 g for 10 s to remove the 
supernatant. The pellet was washed with 135 µl of 70% ethanol and centri­
fuged for 5 min, and the supernatant was removed as before. Samples were 
dried in a heating block at 95°C for 10 s. Before being loaded on the 
sequencer, samples were resuspended in 10 µl HiDi formamide, transferred 
to an ABI plate (both Applied Biosystems), and denatured at 95°C for 3 min. 
Sequencing reactions were run on a PRISM 3130xl Genetic Analyzer (Ap­
plied Biosystems). Samples were viewed and analyzed using Chromas soft­
ware (Technelysium Pty Ltd).
Gene expression analysis
Total RNA was extracted from 8 primary RGP malignant melanomas, 15 
primary vertical growth phase malignant melanomas, and 5 melanoma me­
tastases and processed as described in Scatolini et al. (2010). Commercial 
RNA (BDTM Human Universal Reference Total RNA; Takara Bio Inc.) 
was used as baseline in comparative hybridization experiments on oligonu­
cleotide glass arrays (Human Whole Genome 44K Oligo Microarray Array; 
Agilent Technologies) using a dye­swap duplication scheme. Single channel 
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Flow cytometric analysis of apoptosis
The Annexin V assay was used to detect apoptotic cells. Cells were treated 
with chemotherapeutic agents for 16–24 h, with or without prior DNA 
transfection or shRNA infection. Cells were trypsinized, and all cells (living 
and dead) were pelleted. Cells were resuspended in 400 µl of 1× Binding Buf­
fer (BD; 10× binding buffer, 0.1 M Hepes, pH 7.4, 1.4 M NaCl, and 25 mM 
CaCl2). 5 µl Annexin V–FITC (BD) was added and incubated in the dark at 
room temperature for 15 min. Samples were analyzed on the flow cytometer 
(LSRII) within an hour. Viability dye (5 µg/ml propidium iodide [PI]) was 
added just before reading. The following controls were used to set up com­
pensation and quadrants: unstained cells, cells stained with Annexin V–FITC 
only (no PI), and cells stained with PI only (no Annexin V–FITC). Apop­
totic cell populations included Annexin V–FITC positive, PI negative and 
Annexin V–FITC positive, and PI positive (right top and bottom quadrants 
of scatter plot). Results were analyzed using the FACSDiva software (BD) 
and expressed as mean ± SEM values of three independent experiments per­
formed in triplicate.
Electron microscopy
The Tokuyasu method was used for immunogold localization of p63 
(Tokuyasu, 1980). Cells were seeded at 70% confluency in two 100­mm plates 
and treated with 2 µM paclitaxel for 6 h. 8% formaldehyde + 0.2% glutaral­
dehyde in 100 mM Pipes buffer, pH 7.2, was added to the media (1:1), and 
plates were refrigerated (1 h). Cells were scraped into an Eppendorf tube and 
centrifuged (1,500 rpm for 5 min). The supernatant was discarded, and cells 
were resuspended in Pipes buffer for transport. The pellet was washed twice 
in Pipes buffer, and supernatant was discarded, ensuring removal of fixative. 
The pellet was resuspended in 10% warm gelatin and centrifuged (6,000 rpm 
for 3 min). To solidify, the pellet of cells in gelatin was incubated at 4°C 
(30 min). Gelatin containing the cells was cut into small cubes 1 mm3, 
which were incubated in 2.3 M sucrose at 4°C overnight for cryoprotection. 
Cubes were mounted on specimen pins, excess sucrose was blotted away, 
and the cubes were cryofixed by plunging into liquid nitrogen. Cryosections, 
90­nm thick, were cut from these blocks with glass knives at 100°C 
using an MTXL ultra­microtome with a CRX cryo­adaptation (RMC). 
Groups of sections were picked up on a droplet of 2.3 M sucrose and trans­
ferred onto Pioloform­coated nickel grids. Grids were floated onto standard 
buffer consisting of PBS + 1% BSA + 0.1% sodium azide, pH 7.4. Grids 
were incubated (three times for 5 min) on PBS–0.05 M glycine to remove 
remaining aldehyde groups persisting from the fixation process before being 
washed in incubation buffer (PBS + 0.1% BSA­c [Aurion] + 0.1% azide, pH 
7.4) and transferred onto droplets of primary antibody (anti­p63 antibodies 
H129, 4A4, and H137 [Santa Cruz Biotechnology, Inc.] and anti­mtHsp70 
[Grp75; Abcam]) diluted in incubation buffer (1:50) for overnight incubation 
at 4°C. The primary antibody was removed by passing over six droplets of 
incubation buffer solution, 5 min per droplet, before incubation for 1 h at 
room temperature with the secondary antibody, diluted in incubation buffer 
(1:100). Secondary antibody was removed by passing grids over three drop­
lets of PBS (5 min), and the reaction was fixed by exposing grids to PBS–2% 
glutaraldehyde. Grids were washed over distilled water (three times for 
5 min). Sections were subsequently embedded in 2% methylcellulose/3% ura­
nyl acetate solution in a 9:1 ratio. Sections were examined, and micrographs 
were obtained using a T12 transmission electron microscope (FEI) at an 
accelerating voltage of 120 kV.
Immunohistochemistry: paraffin-embedded tissue
Clinicopathologically characterized, formalin­fixed paraffin­embedded 
material representing benign melanocytic nevi and all stages of melanoma 
development (primary melanoma, recurrent melanoma, and metastases) 
were analyzed for expression of p63 (Ethical approval number 07/QO604/23 
by the East London & The City HA Local Research Ethics committee 
2, UK). The effect of storage of tissue samples on p63 reactivity was notable; 
with increased storage times, a progressive and significant decrease in intensity 
of p63 staining was observed, with evidence of significant decline occurring 
as early as 2 wk of storage (Hameed and Humphrey, 2005; Burford et al., 2009). 
For stable infection with shRNA, the pSUPERIOR.retro.puro vector con­
structs each containing one of three annealed oligonucleotide sequences 
targeting p63 (clones 1, 2, and 3) were transfected into the packaging cell 
line Phoenix cells before introducing the retrovirus into the melanoma cell 
lines. Infected cells were selected using 0.9–1.25 µg/ml puromycin to es­
tablish a stable cell line for shRNA expression that was transcribed in cells 
from a DNA template as a single­stranded RNA molecule. Effects in p63 
mRNA were subsequently analyzed. For p53 knockdown, A375M cells 
were transfected with the stealth RNAi siRNA for p53 (ID 000546; Invit­
rogen; Fenouille et al., 2011). Transfection was performed according to the 
manufacturer’s instructions with the Lipofectamine RNAiMAX transfec­
tion reagent (Invitrogen).
Flow cytometric analysis of translocation of intracellular proteins
Translocation of p63 and p53 between subcellular compartments was quanti­
fied by assessing p63 or p53 fluorescence intensity using a novel flow cytom­
etry technique (Leverrier et al., 2007). The advantages of this method include 
increased sensitivity, requirement for fewer cells, marginal spillover between 
cellular compartments, and reproducibility, which allows quantification of 
relative protein concentration within a cellular compartment. Moreover, data 
from quantification experiments were validated using confocal microscopy to 
confirm purity of the fractions (Fig. 3 D). Three different fluorescent stains 
were used: MitoTracker Orange (CMTMRos; Molecular Probes) for the mi­
tochondria, Hoechst (Bisbenzimide Hoechst 33342; Sigma­Aldrich) for the 
nucleus, and secondary antibodies conjugated to Cy5 (Cy5­conjugated Affi­
niPure F(Ab)2 fragment goat anti–mouse IgG; Jackson ImmunoResearch 
Laboratories, Inc.) for p63 or p53 labeling. Live melanoma cells were incu­
bated with MitoTracker Orange to fluorescently label mitochondria, and 
cells were labeled with anti­p63 or IgG mouse isotype primary antibody and 
Cy5­conjugated anti–mouse secondary antibody followed by Hoechst (to 
label the nuclei). The anti­p63 antibody used (4A4) detected all isoforms of 
p63. Intact A375M cells, characterized by their double positivity to Hoechst 
and MitoTracker Orange labeling, were analyzed. Cells were disrupted using 
a Dounce homogenizer, and the resulting homogenates were reanalyzed by 
flow cytometry. For each cell line, preliminary control experiments included 
MitoTracker Orange or Hoechst fluorescently labeled cells only, confirming 
location of the fractions in the homogenized sample. Hoechst­positive and 
MitoTracker Orange–negative populations were defined as free nuclei; Hoechst­
negative and MitoTracker–positive populations were defined as free mito­
chondria ,and the final region gated comprised intact cells. After gating for 
whole cell, mitochondrial, and nuclear populations, fluorescence intensity of 
p63­Cy5 was analyzed using the FlowJo software (Tree Star). To establish pu­
rity of the nuclear and mitochondrial fractions, homogenized cells were sorted 
according to Hoechst and MitoTracker Orange labeling using the FACSAria 
cell sorter (BD). Sorted fractions were reanalyzed to confirm purity of each 
fraction (Fig. 3 D). Sorted mitochondrial fractions were centrifuged (13,000 g 
for 30 min at 4°C), and the supernatant was discarded. Mitochondrial isolates 
fluorescently labeled with MitoTracker Orange were mounted and visualized 
using confocal microscopy. The nuclear fraction was prepared in the same 
way except centrifugation was performed at 4,500 rpm for 15 min at 4°C 
before mounting isolates onto a slide. Imaging of the intact cells, nuclei, and 
mitochondria by confocal microscopy validated the analysis gates used to 
separate fractions comprising of pure nuclei and mitochondria and not frag­
ments of cells. Further verification of this technique included detection of 
p63 protein by visualizing p63­Cy5 in mitochondrial and nuclear fractions 
using confocal microscopy after fluorescence­activated cell sorting (FACSAria 
flow cytometer; BD; Fig. 3 E). An LSRII (BD) fitted with 488­, 405­, 350–
360­, and 633­nm lasers with FACS Diva software version 4.1.2 was used to 
acquire 30,000 whole cells or 1 million fractionated events, using the Argon 
488­nm laser line and a 575/26­nm band pass filter to detect MitoTracker 
Orange; the UV 350–360 laser and a 440/40­nm band pass filter were used 
to detect Hoechst 33342; the Red HeNe 633­nm line and 660/20­nm band 
pass filter were used to detect Cy5. No compensation was required because 
of the use of separate laser lines to detect fluorophores, which did not display 
any spectral cross talk.
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